Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and ...

Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) is a twice-weekly innovative patch formulation of Rivastigmine for the treatment of mild to moderate dementia associated with Alzheimer ...

The US Food and Drug Administration has approved an expanded indication for the rivastigmine transdermal system (Exelon Patch, Novartis Pharmaceuticals Corporation) to include patients with severe ...

September 4, 2012 — The US Food and Drug Administration (FDA) has approved a 13.3 mg/24 hour dosage strength of the rivastigmine transdermal system (Exelon, Novartis) for patients with mild to ...

In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium. VANCOUVER, BC—In ...

Rivastigmine is a first-line drug in the treatment of dementia associated with Alzheimer's disease and is currently marketed worldwide. About Rivastigmine Multi-Day Transdermal Patch ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

GUILDFORD, England, Sept. 23, 2021 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine ...

Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and ...

Italfarmaco Group adds innovative Alzheimer's disease therapy to its neurology-based product portfolio Italfarmaco Group (Italfarmaco) and Luye Pharma Switzerland AG ("Luye Switzerland"), a fully ...

Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the ...

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the ...